GlassScriptPhysician profile
Ronald M Glick
NPI 1235134412
$91,200.23
in general payments reported to CMS, 2019-2025
28 companies · $11K in 2025
The $11K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $9,349 · 2021: $6,013 · 2022: $9,824 · 2023: $12K · 2024: $17K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $5,983 · Travel and Lodging: $1,259 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,750.00 |
| Food and Beverage | $5,982.89 |
| Travel and Lodging | $1,259.38 |
| Education | $369.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $70,207.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $8,199.49 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $7,488.32 | 2019-2025 | Siliq, Duobrii |
| Sun Pharmaceutical Industries INC. | $852.68 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $806.29 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $663.20 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $522.60 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $479.55 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $417.24 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $401.59 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $219.77 | 2019-2025 | |
| Genzyme Corporation | $205.01 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $193.42 | 2021-2025 | Sotyktu |
| Incyte Corporation | $65.97 | 2022-2025 | Opzelura |
| Mylan Institutional INC. | $63.86 | 2023 | Hulio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $52.91 | 2023-2024 | Zoryve |
| Janssen Scientific Affairs, LLC | $50.24 | 2024 | Tremfya |
| Strata Skin Sciences, INC. | $47.78 | 2025 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $42.85 | 2021-2023 | Valchlor |
| Dermavant Sciences, INC. | $37.37 | 2023-2024 | Vtama |
| Sanofi US Services INC. | $32.55 | 2024 | |
| Prugen, INC. Pharmaceuticals | $31.35 | 2019 | |
| Merck Sharp & Dohme LLC | $28.34 | 2019 | |
| Almirall LLC | $27.05 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.78 | 2023 | Spevigo |
| Journey Medical Corporation | $18.18 | 2025 | |
| Galderma Laboratories, L.P. | $15.17 | 2024 | |
| Mayne Pharma Commercial LLC | $6.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.